LXRX – lexicon pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Lexicon Pharmaceuticals (LXRX) was given a new $6.00 price target by HC Wainwright.
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Lexicon Pharmaceuticals (LXRX) had its price target raised by Citigroup Inc. from $2.10 to $2.30. They now have a "buy" rating on the stock.
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Lexicon Pharmaceuticals (LXRX) had its price target raised by HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.
Form 10-K LEXICON PHARMACEUTICALS, For: Dec 31
Form 8-K LEXICON PHARMACEUTICALS, For: Mar 05
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: McDermott Wendy
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: Martens Rachel Yap
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: Granowitz Craig B
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.